CYRX

CryoPort, Inc. 10-Q Summary

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for CryoPort, Inc., a smaller reporting company incorporated in Nevada. The report covers the three-month period ended June 30, 2008. The Company focuses on manufacturing and selling cryogenic shipping systems for biological materials, specifically transitioning from reusable shippers to a new "CryoPort Express" one-way shipper system. As of August 10, 2008, there were 41,174,703 shares of common stock outstanding.

Key Financial Metrics

Cash Flow: Net cash used in operating activities was $694,914. Net cash provided by financing activities was $683,713, primarily from convertible note borrowings. Net cash used in investing activities was $30,132.

Material Changes vs. Prior Period

• Revenue: Net sales increased 142% to $13,424, driven by introductory sales of the new one-way shipper and reusable product sales, though volumes remain low.
• Net Loss: Net loss increased significantly to $8.22 million, primarily due to a non-cash loss on extinguishment of debt of $6,902,941 resulting from an amendment to the October 2007 convertible debentures.
• Interest Expense: Increased to $555,769 from $58,000, driven by the amortization of debt discounts and financing fees associated with convertible debentures.
• Inventory: Increased 60% to $195,036 due to raw material purchases in anticipation of the new product launch.
• Debt Structure: The Company amended its October 2007 debentures in April 2008, deferring principal payments and reducing warrant exercise prices, which triggered the debt extinguishment loss. A new $1.25 million convertible debenture was issued in May 2008.

Guidance, Outlook, Risks, and Contingencies

Going Concern: The filing explicitly states that substantial doubt exists regarding the Company's ability to continue as a going concern. This is due to recurring losses, negative cash flows from operations, and a working capital deficit. Management relies on recent financing proceeds (approx. $2.0 million cash on hand as of August 10, 2008) to fund operations and the launch of the CryoPort Express system.

Outlook: Management plans to focus all resources on the launch of the CryoPort Express One-Way Shipper. They intend to minimize cash expenditures by utilizing stock-based compensation for consultants and employees and maintaining lean personnel levels.

Risks:

• Lack of firm orders or commitments from key customers for the new product line.
• Dependence on additional capital to fund operations and product development.
• High debt service obligations and potential dilution from convertible notes and warrants.
• Concentration of credit risk in the bio-tech and pharmaceutical industries.

Unusual Items: The $6.9 million loss on debt extinguishment is a non-cash item resulting from the fair value adjustment of warrants and the write-off of deferred financing costs due to the debt amendment.

Investor Verification Checklist

• Debt Extinguishment Details: Verify the specific terms of the April 30, 2008 amendment to the October Debentures and the calculation of the $6.9 million loss.
• Liquidity Runway: Confirm the current cash burn rate and whether the $2.0 million cash balance (as of August 2008) is sufficient to reach profitability or secure further financing.
• Product Launch Status: Assess the timeline and market reception of the CryoPort Express One-Way Shipper, as this is the primary driver for future revenue.
• Dilution Impact: Review the total number of warrants and convertible notes outstanding, noting the reduced exercise prices ($0.60) on the amended October Warrants.
• Related Party Transactions: Review the status of related-party notes payable, noting that some payments were missed but covered by a 120-day grace period.